More recently trastuzumab deruxtecan, an antibody − drug conjugate consisting of trastuzumab covalently linked to topoisomerase I inhibitor, has been approved in HER2 positive gastric cancer [8]. This evidence concerns the gene ERBB2 and gastric cancer.